Answers are grounded in this paper and cite their sources.
Retrospective study develops a model predicting survival in triple-negative breast cancer patients, suggesting individualized treatment options.
The binary pathological complete response (pCR) status of triple-negative breast cancer (TNBC) patients after neoadjuvant chemotherapy (NAC) inadequately captures risk heterogeneity for prognosis. Therefore, this study aimed to develop a machine learning-based survival model to predict individualized overall survival (OS) in TNBC patients with pCR after NAC. This retrospective study utilized a Dutch nationwide cohort of TNBC patients, diagnosed between 2013 and 2021. We trained a survival model on the data using nested 5-fold cross-validation. Patients were stratified into a low- and high-risk group, based on the predicted survival probabilities. A total of 2642 patients with a pCR post-NAC were included, of whom 2620 were used in the final analysis. The survival model achieved good discrimination (C-index 0.754). Risk stratification identified a high-risk subgroup ( n = 495, 18.9%) with significantly worse survival compared to the low-risk group (5-year OS 85.2% vs. 96.7%, log-rank P < 0.001). Pre-treatment nodal status (cN) was the strongest predictor, followed by age and clinical tumor stage (cT). This nationwide analysis demonstrates that TNBC patients achieving pCR remain a heterogeneous group with distinct survival outcomes. Machine learning-based survival modeling may enable individualized risk prediction using routinely collected clinical variables and may guide future post-surgical treatment escalation for high-risk TNBC patients despite pCR.
No takes yet. Share an insight, caveat, or question.
Kwakkenbos et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: